scholarly journals Efficacy and safety of Buzhong Yiqi Decoction in improving cancer-related fatigue and immunity of cervical carcinoma patients

Medicine ◽  
2021 ◽  
Vol 100 (49) ◽  
pp. e27938
Author(s):  
Juan Hu ◽  
Xia Li ◽  
Yanping Fang ◽  
Jin Peng
Keyword(s):  
Cervical Carcinoma ◽  
Efficacy And Safety ◽  
Cancer Related Fatigue

A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9017-9017 ◽  
Author(s):  
Yuanjue Sun ◽  
Baorui Liu ◽  
Ping Liu ◽  
Changping Wu ◽  
Rongsheng Zheng ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Oral Administration ◽  
Primary Endpoint ◽  
Side Effect ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Cancer Related Fatigue ◽  
Significant Difference

9017 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of many commonly used chemotherapeutic. This side effect of chemotherapy can be debilitating and effective treatment for CIPN remains elusive. Previous studies demonstrated that Acetyl-L-Carnitine (ALC) is effective in attenuating CIPN, controlled study is needed to substantiate ALC’s effect in treatment of CIPN. Methods: This study was designed to evaluate the efficacy and safety of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablet (oral administration) in the treatment of CIPN. It was a prospective, randomized, double-blinded, placebo-controlled and paralleled clinical study (registration No. 2007L03540). Of 239 subjects enrolled in the study (NCI grade 2 or above), 118 subjects received 3g/day ALC orally for 8 weeks and 121 received placebo. Primary endpoint was set as improvement of peripheral neuropathy at least 1 grade and assessment was made in week 4, 8 and 12 after enrollment. Results: In full analyses set (FAS) and per-proposal set (PPS), the peripheral sensory neuropathy was significantly ameliorated in ALC group with 50.5% and 51.6% patients meeting the primary endpoint at week 8 and 12 respectively while only 24.1% and 23.1% of patients in the placebo group at week 8 and 12 respectively (p<0.001 in both sets). Secondary endpoint such as nerve electrophysiological test and Physical Condition Score (Karnofsky performance status, KPS) were also significantly improved in patients with ALC treatment (in FAS, P=0.0463 and P=0.022; in PPS, P=0.0076and P=0.0064, respectively). Cancer-related fatigue was significantly alleviated after ALC treatment in PPS (P=0.0135). Safety: 236 subjects were included in safety assessment and 41 patients experienced 62 adverse events during the course of study. There was no significant difference in AE/SAE incidence between the two groups (P=0.3903). Conclusions: Oral administration of ALC is effective in attenuating CIPN as well as in reducing cancer-related fatigue and improving physical conditions in cancer patients. The treatment of oral ALC is safe and well tolerated.

Efficacy and safety of neoadjuvant paclitaxel, ifosfamide, and cisplatin (TIP) chemotherapy in locally advanced squamous cell cervical carcinoma followed by radical surgery: A single institution experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16532-e16532
Author(s):  
Giuseppa Scandurra ◽  
Giuseppe Scibilia ◽  
Giuseppe Luigi Banna ◽  
Helga Maria Alessandra Lipari ◽  
Gabriella D'Agata ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Figo Stage ◽  
3D Ultrasound ◽  
Pelvic Lymphadenectomy ◽  
Efficacy And Safety ◽  
Stage Disease ◽  
Abdominal Mri ◽  
Squamous Cell Cervical Carcinoma

e16532 Background: The management of locally advanced squamous cell cervical carcinoma includes chemoradiotherapy or neoadjuvant cisplatin based chemotherapy followed by surgery, that may offer specific advantages a better potential activity. Porpouse: To evaluate efficacy and safety of TIP neoadjuvant chemoregimen in patiens affects by local advanced squamous cell cervical carcinoma. Methods: July 1997 - December 2011 were treated at our institution 165 patients with locally advanced squamous cell cervical carcinoma of whom 143 are evaluable. Regimen: Ifosfamide 5000 mg/mq ev day 1 iv in 24 h ; Mesna 5000 mg/mq ev day 1 iv in 24 h ; Paclitaxel 175 mg/mq ev day 2; Cisplatin 75 mg/mq ev day 2; every 3 weeks for a total of three courses. Tumor extension was assessed clinically and by abdominal MRI, PET WB and 3D ultrasound at baseline and after three courses.The operable patients after TIP chemoterapy underwent radical hysterectomy and pelvic lymphadenectomy. The median age 53 ( range 24-79 yrs), clinical FIGO stage Ib 2 2 pts(1%) , IIb 59 pts(41%), IIb bulky 68 pts (48%), III-IV 14 pts (10%), histological subtype SCC 138 pts (96%) and adenocarcinoma 5 pts ( 4%). Results: After neoadjuvant chemiotherapy 132 pts (92%) underwent surgery. Post-chemotherapy pathological response was pCR 25 pts (19%), PR1 16 pts (12%), PR2 80 pts (61%), SD 10 pts (7%), PD 1 pt (1%). Median numbers of courses of TIP administrated was 3 ( range 1-3). Treatments was delay or withdrawal in 22 pts ( 16%). Treament limiting toxicities were, Neutropenia 11 pts (52%), Anemia 10 pts (45%),Thrombocytopenia 7 pts (33 %), Renal failure 3 pts (14 %), Allergic reaction 3 pts (14%), Vomiting 3 pts (14%), Febrile neutropenia 2 pts (10%), Hypopotassiemia1 pt (5%), Atrial fibrillation 1pt( 5%), Pneumonia 1 pt (5%). Conclusions: In our experience neoadjuvant TIP was feasible, effective with 92% resection rate and active in an older and higher stage disease enriched series than reported in previous clinical trials.

scholarly journals Efficacy and safety of acupuncture in patients with cancer-related fatigue

Medicine ◽  
2020 ◽  
Vol 99 (42) ◽  
pp. e22759
Author(s):  
Tai-Jun Jiang ◽  
Feng-Ya Zhu ◽  
Li-Jie Tang ◽  
Zheng-Kang Liu ◽  
Xi Wu
Keyword(s):  
Efficacy And Safety ◽  
Patients With Cancer ◽  
Cancer Related Fatigue

Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study

2021 ◽  
Author(s):  
Uttiya Deb ◽  
Sandip Mukhopadhyay ◽  
Biswamit Bhattacharya ◽  
Sanatan Banerjee ◽  
Supreeti Biswas
Keyword(s):  
Cancer Patients ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Cancer Related Fatigue ◽  
Severe Fatigue ◽  
Curative Radiotherapy ◽  
Clinical Trials Registry

The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL). A prospective randomized controlled study was conducted, enrolling 80 cancer patients experiencing moderate or severe fatigue following at least three cycles of chemotherapy or a course of palliative/curative radiotherapy. Patients received either oral modafinil 100 mg or dexamethasone 4 mg daily for 14 days. Levels of fatigue, QoL and symptom severity were compared after 14–21 days. Both drugs were efficacious and safe in the management of fatigue and QoL. However, modafinil performed marginally better. Although modafinil demonstrated marginal superiority, both modafinil and dexamethasone can improve fatigue and QoL in cancer patients. Clinical trials registry of India: CTRI/2018/05/014046 (www.ctri.nic.in)

Sign in / Sign up

Export Citation Format

Share Document